Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Advanced technology: regulatory requirements during the development and marketing phase of nanotechnology medicines
- In: G1 - The 10 best industrial pharmacy contributions of 2009 on Saturday, 5 September 2009, 9:15-11:40
- At: Istanbul (Turkey) (2009)
- Type: Presentations + Posters
- By: TERCAN, Tugba Nevriye (Hacettepe University, Health Science Instute, Ankara, Turkey)
- Co-author(s): Çapan, Yilmaz (Hacettepe University, Faculty of Pharmacy, Dept. of Pharmaceutical Technology, Ankara, Turkey)
Sam, Tom (Schering-Plough, Oss, Netherlands) - Abstract:
Ten years from now nanotechnology-based medicines are expected to be a large proportion of the new medicines to be approved for marketing authorization. After an extensive introduction into the scientific aspects of this new technology the thesis describes how the current EU Union), USA and Turkish legislation deals with nanotechnology products.
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023